ARS Pharmaceuticals

SPRY - ARS Pharmaceuticals • Financials

ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered and reliable nasal spray.

Complete and updated financials table with all primary indicators: Net Income, Revenue, EBITDA, Margin, ROE, Dividends

Year
12/2018
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
12/2019
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
12/2020
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
12/2021
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
12/2022
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
12/2023
0
-67
-
L
L
231
L
-228
-
-69
-0
7
-69
0
0
-
-
12/2024
89
-3
-
9%
0.08
257
3%
-314
-
-1
-8
72
-9
0
0
-
-
12/2025
84
-178
-
L
L
114
L
-149
-
-193
-8
105
-201
0
0
-
-